Cite
HARVARD Citation
Levesque, B. et al. (n.d.). P051 Phase 1a Safety and Pharmacokinetic Effects of GB004, a Novel Prolyl Hydroxylase Inhibitor and Potential Therapy for Inflammatory Bowel Disease. American journal of gastroenterology. p. . [Online].